Novartis Trileptal Has Fewer Hemopoietic, Dermatologic AEs Than Tegretol

Novartis' Trileptal labeling indicates that the anticonvulsant may be associated with fewer serious hemopoietic and dermatologic adverse events than the company's older antiseizure drug Tegretol.